Diamyd Medical's Phase III study published in the New England Journal of
Medicine
An article with the results of Diamyd Medical's European Phase III study of the
antigen-based diabetes therapy Diamyd® has been published in the scientific
journal the New England Journal of Medicine. The now published results were
previously presented at the American Diabetes Association’s 71st Scientific
Sessions in San Diego, California, USA, on June 28, 2011.
The title of the published article is “GAD65 Antigen Therapy in Recently
Diagnosed Type 1 Diabetes Mellitus”. The authors are J. Ludvigsson, D. Krisky,
R. Casas, T. Battelino, L. Castaño, J. Greening, O. Kordonouri, T. Otonkoski, P.
Pozzilli, J-J. Robert, H.J. Veeze and J. Palmer.
The article is available via the New England Journal of Medicine’s website
(www.nejm.org), and will also be published in the printed edition.
Results from Diamyd Medical’s European Phase III study with Diamyd® were first
reported in May 2011. The study did not meet the primary efficacy endpoint of
preserving beta cell function, as measured by meal-stimulated C-peptide,
although a small positive effect was seen. Safety data from the study showed
that Diamyd® was well tolerated, as demonstrated by a similar number of adverse
events reported in the groups treated with Diamyd® and in the placebo group.
For more information, please contact:
Peter Zerhouni, President and CEO Diamyd Medical AB
Phone: +46 8 661 00 26. E-mail: press@diamyd.com
